Skip to main content
OpenTrials
Recruiting

NCT Number: NCT04964869

Efficacy of Prophylactic Epinephrine Solution Injection in Prevention of Delayed Post-sphincterotomy

Bleeding is the most frequently reported serious complication of endoscopic sphincterotomy, and severe bleeding has occurred in about 1% to 2% of patients. Endoscopic injection of epinephrine is the most commonly used, effective, and least expensive method for the management of post- sphincterotomy bleeding. However, the efficacy of prophylactic saline-epinephrine solution injection to prevent delayed EST bleeding when transient bleeding During ERCP has not been established.

Recruiting

Interested in participating?

Request Info

Key information

Age range

20 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

China Medical University Hospital

Taichung, North Dist., 404332, Taiwan

Location status: Recruiting

Location contact

Shih-Chieh Chuang, MD

CONTACT

[email protected]

+886-975680839

About this study

Backgroud:

Bleeding is the most frequently reported serious complication of endoscopic sphincterotomy, and severe bleeding has occurred in about 1% to 2% of patients. Endoscopic injection of epinephrine is the most commonly used, effective, and least expensive method for the management of post- sphincterotomy bleeding. However, the efficacy of prophylactic saline-epinephrine solution injection to prevent delayed EST bleeding when transient bleeding During ERCP has not been established.

Study Rationale:

The hypotheses of the study is the prophylactic saline-epinephrine solution injection affects incidence of delayed post-EST bleeding.

Study Design:

A single blinded parallel group, multiple center, randomized controlled trial. The sample size is estimated 400 (200 in injection group and 200 in non-injection group), The primary outcome is the rate of delayed EST bleeding within 30 days of ERCP.

Study Objectives:

Primary objective: the rate of post-EST bleeding within 30 days of ERCP Secondary objectives: the rate of post-ERCP advese effect, the increasing procedure time because of hemostasis, the need for angiographic/endoscopic hemostasis times.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 20 years or older.
  • Ability to give informed consent.
  • An naive major papilla.
  • Transient bleeding after endoscopic sphincterotomy
  • Bleeding less than 30 secs when end of procedure

Exclusion criteria

  • Prior endoscopic sphincterotomy.
  • Thrombocytopenia (platelets <50,000/mm3).
  • Liver cirrhosis (Child A-C)
  • CKD stage 4-5 and dialysis.
  • Allergy to epinephrine
  • Prolonged PT/APTT (INR>1.5)
  • Had exposure any antithrombotic or antiplatelet agent in recent 7 days and/or will take those agents in one month after EST
  • Ampulla Vater tumor
  • Active GI bleeding
  • Pregnancy
  • Limited visibility when immediate bleeding after sphincterotomy
  • Still bleeding after 30 secs when end of procedure
  • Recurrent bleeding during ERCP

Treatment and study plan

epinephrine solution injection

Procedure

epinephrine solution injection at least 1 ml to the post- sphincterotomy wound

Primary outcomes

  1. post EST bleeding rate

    Time frame: 30 days

    delay post-sphincterotomy bleeding rate

Study contacts

Contact information is provided by the study sponsor or research team.

Shih-Chieh Chuang, MD

CONTACT

[email protected]

+886-975680839

Wen-Hsin Huang, MD

CONTACT

[email protected]

+886-4-2205-2121 ext. 2233

Sponsors and collaborators

Lead sponsor

Wen-Hsin Huang

Other

Registry information

Official study title

Efficacy of Prophylactic Epinephrine Solution Injection in Prevention of Delayed Post-sphincterotomy Bleeding in Patients with Transient Bleeding During ERCP

Important dates

Study start
2021
Primary completion
2030
Study completion
2030
First posted
Jul 16, 2021
Registry last updated
Oct 24, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.